Download PDF
TumorDiagnostik & Therapie 2019; 40(03): 176-179
DOI: 10.1055/a-0824-9953
Schwerpunkt Pankreaskarzinom
© Georg Thieme Verlag KG Stuttgart · New York

Supportivtherapie beim Pankreaskarzinom

Marianne Sinn
Further Information

Publication History

Publication Date:
03 April 2019 (online)

Also available at
    Permissions and Reprints

Neben der systemischen Behandlung ist bei Patienten mit einem fortgeschrittenen Pankreaskarzinom eine optimale Supportivtherapie zur Erhaltung und Verbesserung der Lebensqualität von besonderer Bedeutung. Der folgende Beitrag fasst die wichtigsten Aspekte zusammen.
 

  • Literatur

  • 1 Ryan DP, Hong TS, Bardeesy N. Pancreatic Adenocarcinoma. N Engl J Med 2014; 371: 1039-1049
    CrossrefPubMedGoogle Scholar
  • 2 Laquente B, Calsina-Berna A, Carmona-Bayonas A. et al. Supportive care in pancreatic ductal adenocarcinoma. Clin Transl Oncol 2017; 19: 1293-1302
    CrossrefPubMedGoogle Scholar
  • 3 Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F. et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 2013; 31: 23-29
    PubMedGoogle Scholar
  • 4 Burris HA, Moore MJ, Andersen J. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413
    CrossrefPubMedGoogle Scholar
  • 5 Laquente B, Macarulla T, Bugés C. et al. Quality of life (QoL) of patients (pts) with metastatic pancreatic cancer (mPAC) initiating first-line chemotherapy (CT) in routine practice. Annals Oncol 2017; 28: mdx369.135
    PubMedGoogle Scholar
  • 6 Hui D, Bruera E. Integrating palliative care into the trajectory of cancer care. Nat Rev Clin Oncol 2016; 13: 159-171
    CrossrefPubMedGoogle Scholar
  • 7 Blom JW, Osanto S, Rosendaal FR. High risk of venous thrombosis in patients with pancreatic cancer. Eur J Cancer 2006; 42: 410-414
    CrossrefPubMedGoogle Scholar
  • 8 Encke A, Haas S, Kopp I. et al. S3-LeitlinieProphylaxe der venösen Thromboembolie (VTE). https://www.awmf.org/leitlinien/detail/ll/003-001.html
    PubMedGoogle Scholar
  • 9 Pelzer U, Opitz B, Deutschinoff G. et al. Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. J Clin Oncol 2015; 33: 2028-2034
    CrossrefPubMedGoogle Scholar
  • 10 Carrier M, Abou-Nassar K, Mallick R. et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med 2018; DOI: 10.1056/NEJMoa1814468.
    CrossrefPubMedGoogle Scholar
  • 11 Hach-Wunderle V, Konstantinides S, Riess H. et al. S2K-Leitlinie Venenthrombose und Lungenembolie: Diagnostik und Therapie. https://www.awmf.org/leitlinien/detail/ll/065-002.html
    PubMedGoogle Scholar
  • 12 Raskob GE, van Es N, Verhamme P. et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 2018; 378: 615-624
    CrossrefPubMedGoogle Scholar
  • 13 Kitano M, Yamashita Y, Tanaka K. et al. Covered self-expandable metal stents with an anti-migration system improve patency duration without increased complications compared with uncovered stents for distal biliary obstruction caused by pancreatic carcinoma: a randomized multicenter trial. Am J Gastroenterol 2013; 108: 1713-1722
    CrossrefPubMedGoogle Scholar
  • 14 Seufferlein T. (Koord.) S3-Leitlinie zum exokrinen Pankreaskarzinom. https://www.awmf.org/leitlinien/detail/ll/032-010OL.html
    PubMedGoogle Scholar
  • 15 Moss AC, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev 2006; 2: CD004200
    PubMedGoogle Scholar
  • 16 Zorger N, Feuerbach S. Technik der perkutanen transhepatischen Cholangio-Drainage (PTCD). J Gastroenterol Hepatol Erkrank 2010; 8: 21-26
    PubMedGoogle Scholar
  • 17 Siegmund E, Lohr JM, Schuff-Werner P. The diagnostic validity of non-invasive pancreatic function tests – a metaanalysis. Z Gastroenterol 2004; 42: 1117-1128
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Mössner J, Keim V. Pancreatic Enzyme Therapy. Dtsch Arztebl Int 2011; 108: 578-582
    PubMedGoogle Scholar
  • 19 Domínguez-Muñoz JE, Iglesias-García J, Iglesias-Rey M. et al. Effect of the administration schedule on the therapeutic efficacy of oral pancreatic enzyme supplements in patients with exocrine pancreatic insufficiency: a randomized, three-way crossover study. Aliment Pharmacol Ther 2005; 21: 993-1000
    CrossrefPubMedGoogle Scholar
  • 20 Kerner W. Pankreas-Diabetes: Häufig fehldiagnostiziert. Dtsch Arztebl 2018; 115 DOI: 10.3238/PersDia.2018.04.27.02.
    CrossrefPubMedGoogle Scholar
  • 21 Maeda H, Hanazaki K. Pancreatogenic diabetes after pancreatic resection. Pancreatol 2011; 11: 268-276
    CrossrefPubMedGoogle Scholar
  • 22 Hart PA, Bellin MD, Andersen DK. et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol 2016; 1: 226-237
    PubMedGoogle Scholar
  • 23 Ripamonti CI, Bandieri E, Roila F. et al. Management of cancer pain: ESMO Clinical Practice Guidelines. Annals Oncol 2011; 22 (Suppl. 06) vi69-vi77
    CrossrefPubMedGoogle Scholar
  • 24 Drewes AM, Campbell CM, Ceyhan GO. et al. Pain in pancreatic ductal adenocarcinoma: A multidisciplinary, International guideline for optimized management. Pancreatol 2018; 18: 446-457
    CrossrefPubMedGoogle Scholar
  • 25 Gärtner S, Krüger J, Aghdassi AA. et al. Nutrition in Pancreatic Cancer: A Review. Gastrointest Tumors 2016; 2: 195-202
    CrossrefPubMedGoogle Scholar
  • 26 Pakhomov SV, Jacobsen SJ, Chute CG. et al. Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manag Care 2008; 14: 530-539
    PubMedGoogle Scholar
  • 27 Basch E, Deal AM, Dueck AC. et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA 2017; 318: 197-198
    CrossrefPubMedGoogle Scholar
  • 28 Heiberg T, Nordby T, Kvien TK. et al. Development and preliminary validation of the pancreatic cancer disease impact score. Support Care Cancer 2013; 21: 1677-1684
    CrossrefPubMedGoogle Scholar